SpyGlass Pharma to Participate in Upcoming Investor Conferences
Webcasts for SpyGlass Pharma’s Citi fireside chat and H.C. Wainwright presentation will be available on the company’s Investor Relations website.
Rhea-AI Summary
SpyGlass Pharma (SGP) will participate in three investor conferences in September 2026, featuring meetings, a fireside chat and a corporate presentation.
Events include the Wells Fargo 21st Annual Healthcare Conference on September 9, Citi’s 2026 Biopharma Back to School Conference on September 10, and the H.C. Wainwright 28th Annual Global Investment Conference on September 14. Webcasts for the Citi fireside chat and H.C. Wainwright presentation will be available via the company’s Investor Relations website.
Positive
- None.
Negative
- None.
News Market Reaction – SGP
In the Sep 2 session, SGP gained 5.42%, reflecting a notable positive market reaction. Argus tracked a peak move of +2.8% during that session. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility. Trading volume was above average at 1.8x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
IRVINE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today announced that members of the executive management team will participate in the following upcoming conferences:
Wells Fargo 21st Annual Healthcare Conference
Date: Wednesday, September 9, 2026
Format: 1x1 Meetings only
Citi’s 2026 Biopharma Back to School Conference
Date: Thursday, September 10, 2026
Time: 10:40 a.m. ET
Format: Fireside Chat and 1x1 Meetings
H.C. Wainwright 28th Annual Global Investment Conference
Date: Monday, September 14, 2026
Time: 1:30 p.m. ET
Format: Corporate Presentation & 1x1 Meetings
A live webcast and subsequent replay of the Citi fireside chat and H.C. Wainwright presentation can be accessed via the Investor Relations section of the Company website at www.spyglasspharma.com.
About SpyGlass Pharma
SpyGlass Pharma is a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The Company’s mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation.
The SpyGlass Pharma platform, a novel, non-bioerodible drug delivery technology, is designed to be used with various well-established, approved medicines, including bimatoprost and other small molecules, providing flexibility to potentially treat a range of conditions in the front and back of the eye.
The Company was founded in 2019 by Malik Y. Kahook, M.D. and Glenn Sussman to solve the lack of ophthalmic innovations that capitalize on durable treatment options. The SpyGlass Pharma platform was originally developed in the Sue Anschutz-Rodgers Eye Center at the University of Colorado Anschutz School of Medicine.
Media Contact:
Nami Surendranath
+1 (402) 507-6757
nsurendranath@dnacommunications.com
Investor Contact:
Ami Bavishi or Nick Colangelo
Gilmartin Group LLC
investors@spyglasspharma.com
